Head & Neck Cancers | Specialty

Research Leader Discusses FDA-Funded Immunotherapy for Head and Neck Cancer

September 29th 2015

Brett Miles, MD, DDS, discusses the potential of ADXS11-001 in HPV-associated head and neck cancer and other emerging therapies and treatment strategies.

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

September 29th 2015

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Dr. Hisham Mehanna on Quality of Life Differences in Head and Neck Squamous Cell Cancer

September 26th 2015

Hisham Mehanna, MBChB, PhD, Chair, Head and Neck Surgery, Director, Institute of Head and Neck Studies and Education at University of Birmingham, discusses differences in the quality of life (QoL) and functional outcomes of treatment between HPV-positive and HPV-negative head and neck squamous cell cancer patients (HNSCC).

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

September 26th 2015

More than a fifth of patients with previously treated metastatic nasopharyngeal carcinoma showed a measurable response when treated with the immune checkpoint inhibitor pembrolizumab.

Dr. Mell on Toxicities Associated With GL-ONC1 for Head and Neck Cancer

September 23rd 2015

Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

FDA Awards Research Grants for 18 Rare Diseases, Including HPV-Related Oropharyngeal Cancer

September 22nd 2015

Eighteen new research grants, totaling more than $19 million, have been awarded by the FDA for product development in rare diseases such as HPV-related head and neck cancer and recurrent glioblastoma.

HPV DNA Detected in Mouthwash Predicts Oral Cancer Recurrence

August 26th 2015

Patients who have HPV 16 DNA in their saliva following treatment of their oropharyngeal cancer are more likely to have their cancer recur, and a prospective cohort study has shown that a simple mouth rinse can be used to detect it.

Oncolytic Virus Shows Promise in Advanced Head and Neck Cancer

August 19th 2015

The attenuated vaccinia virus GL-ONC1 demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy for patients with locoregionally advanced head and neck carcinoma in a recent phase I study.

Immunotherapy May Hold the Key to Attacking HPV-Associated Cancers

August 14th 2015

An improved understanding of the natural history of HPV, its interaction with the host immune system, and the distinct molecular alterations underlying HPV-positive cancers, are fueling development of new drugs, particularly immunotherapies geared toward generating an HPV-specific immune response.

Efficacy Maintained, QoL Improved With Radiation Dose Reductions in Oropharyngeal Cancer

July 24th 2015

Barbara Ann Burtness, MD, discusses the impact of two studies examining reductions in radiation and chemotherapy dose in low-risk HPV-associated oropharyngeal cancer.

Pembrolizumab Benefit in SCCHN Confirmed in Expansion Study

July 24th 2015

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers

July 24th 2015

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.

Olanzapine Shown to Control CINV in Patients With Esophageal, Head and Neck Cancer

June 15th 2015

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

May 29th 2015

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Dr. Loren Scott Michel on HPV-Associated Oropharyngeal Cancer

April 1st 2015

Loren Scott Michel, MD, Assistant Professor Medicine, Washington University, medical oncologist Siteman Cancer Center, discusses the link between human papillomavirus (HPV) and oropharyngeal cancers.

Investigational Therapies for Thyroid Cancer

March 27th 2015

Frontline Treatment Selection in RAI-Refractory DTC

March 27th 2015

Optimizing Treatment With Lenvatinib in Thyroid Cancer

March 27th 2015

Lenvatinib in RAI-Refractory Thyroid Cancer

March 27th 2015

DECISION Trial Supports Sorafenib in Thyroid Cancer

March 27th 2015